Skip to main content
OpenTrials
Completed

NCT Number: NCT02822131

Phosphate in Blood Pressure Regulation

High dietary phosphate intake in the general population is associated with a higher risk for developing kidney disease and cardiovascular disease with an increased overall mortality. Whereas the effects of high phosphate intake on general health become clearer, almost nothing is known about underlying mechanisms. More recently, the investigators and others found in animal models that FGF23 stimulates the renal NaCl cotransporter NCC, the target of thiazide diuretics, and that increased NCC activity may increase blood pressure. The investigators could also show that increasing dietary phosphate intake in mice, increases FGF23 and NCC activity within 3 days. Thus, the objective of this single-centre observational cross-over study including 20-45 year old healthy male probands is to elucidate the role of dietary phosphate on blood pressure regulation and renal handling of sodium chloride in healthy subjects. Further the impact of dietary phosphate intake on the regulation of phosphaturic hormones and other factors regulation blood pressure will be investigated. In addition, the investigators will examine whether phosphate intake modulates gut microbiome composition. The primary outcome in this study is the change in blood pressure in healthy subjects on low-phosphate diet compared to healthy subjects on high-phosphate diet. In addition, to assess changes in NCC activity as the main mechanism of phosphate-sensitive blood pressure regulation, renal sodium chloride excretion after administration of hydrochlorothiazide will be measured. The secondary outcomes of this study are: changes in renal phosphate, calcium and potassium excretion, changes in phosphate regulation hormones such as 25-OH-Vit. D, 1,25-(OH)2-Vit. D, PTH, FGF23, dopamine in plasma and urine, changes in plasma and urinary aldosterone levels, changes in sodium/chloride-cotransporter NCC and NaPi-IIa assessed from urinary exosomes, and changes in stool phosphate excretion and gut microbiome composition.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Zurich, Nephrology

Zurich, Canton of Zurich, 8091, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 20-45 year old healthy male subjects

Exclusion criteria

  • - Kidney disease (defined by eGFR < 90 ml/min or microalbuminuria (> 30mg/d))
  • Diabetes mellitus
  • Hypertension (RR > 140/85 mmHg)
  • Hypotension (RR < 90/60 mmHg)
  • any regular medication
  • non-Western type diet e.g. vegetarian, vegan etc.
  • History of kidney stones
  • Allergy to sulphonamides or penicillins
  • Hereditary fructose intolerance
  • known hypersensitivity or allergy to class of drugs used in this study
  • Glaucoma
  • Vitamin D deficiency (< 20 ng/ml)
  • Hyper- or Hypoparathyroidism
  • Hypo- or hyperaldosteronism
  • Participation in any other study

Treatment and study plan

sodium phosphate

Dietary Supplement

sevelamer, sodium bicarbonate, sodium chloride

Drug

Primary outcomes

  1. Change in blood pressure

    Time frame: 5 days

  2. Change in renal sodium chloride excretion

    Time frame: 5 days

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

The Effect of Dietary Phosphate Intake on Blood Pressure Regulation and Renal Sodium Chloride Excretion in Healthy Male Volunteers

Acronym: Phos-RR

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Jul 4, 2016
Registry last updated
Jul 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.